IMS denying any representing business for Zuellig.

Published: 2003-09-22 06:56:00

Updated: 2003-09-22 06:56:00

IMS Health made it clear over the Yakup press headline news titled "An upheaval sign in drug distribution communities over Zuellig issues" dated on Sept. 15 that IMS transmitted informations directly to Zuellig upon wholesaler's request instead of wholesaler's direct supplies to Zuellig, which sh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK